RESUMEN

Congenital toxoplasmosis (CT) is a known cause of hearing loss directly caused by Toxoplasma gondii. Hearing loss might result from sensory, neural, or sensorineural lesions. Early treated infants rarely develop hearing loss, but retinochoroidal lesions, intracranial calcifications and hydrocephalus are common. In this study, we aimed to evaluate the brain evoked hemodynamic responses of CT and healthy infants during four auditory stimuli: mother infant directed speech, researcher infant directed speech, mother reading and researcher recorded. Children underwent Transitionally Evoked Otoacoustic Emission Auditory Testing and Automated Brainstem Auditory Response tests with normal auditory results, but with a tendency for greater latencies in the CT group compared to the control group. We assessed brain hemodynamics with functional near-infrared spectroscopy (fNIRS) measurements from 61 infants, and we present fNIRS results as frequency maps of activation and deactivation for each stimulus. By evaluating infants in the three first months of life, we observed an individual heterogeneous brain activation pattern in response to all auditory stimuli for both groups. Each channel was activated or deactivated in less than 30% of children for all stimuli. There is a need of prospective studies to evaluate if the neurologic or auditory changes course with compromise of children outcomes.

Asunto(s)

RESUMEN

BACKGROUND: Intrathecal injection of voltage-sensitive calcium channel blocker peptide toxins exerts analgesic effect in several animal models of pain. Upon intrathecal administration, recombinant Phα1ß exerts the same analgesic effects as the those of the native toxin. However, from a clinical perspective, the intrathecal administration limits the use of anesthetic drugs in patients. Therefore, this study aimed to investigate the possible antinociceptive effect of intravenous recombinant Phα1ß in rat models of neuropathic pain, as well as its side effects on motor, cardiac (heart rate and blood pressure), and biochemical parameters. METHODS: Male Wistar rats and male Balb-C mice were used in this study. Giotto Biotech® synthesized the recombinant version of Phα1ß using Escherichia coli expression. In rats, neuropathic pain was induced by chronic constriction of the sciatic nerve and paclitaxel-induced acute and chronic pain. Mechanical sensitivity was evaluated using von Frey filaments. A radiotelemeter transmitter (TA11PA-C10; Data Sciences, St. Paul, MN, USA) was placed on the left carotid of mice for investigation of cardiovascular side effects. Locomotor activity data were evaluated using the open-field paradigm, and serum CKMB, TGO, TGP, LDH, lactate, creatinine, and urea levels were examined. RESULTS: Intravenous administration of recombinant Phα1ß toxin induced analgesia for up to 4 h, with ED50 of 0.02 (0.01-0.03) mg/kg, and reached the maximal effect (Emax = 100% antinociception) at a dose of 0.2 mg/kg. No significant changes were observed in any of the evaluated motor, cardiac or biochemical parameters. CONCLUSION: Our data suggest that intravenous administration of recombinant Phα1ß may be feasible for drug-induced analgesia, without causing any severe side effects.

RESUMEN

Background: Intrathecal injection of voltage-sensitive calcium channel blocker peptide toxins exerts analgesic effect in several animal models of pain. Upon intrathecal administration, recombinant Phα1β exerts the same analgesic effects as the those of the native toxin. However, from a clinical perspective, the intrathecal administration limits the use of anesthetic drugs in patients. Therefore, this study aimed to investigate the possible antinociceptive effect of intravenous recombinant Phα1β in rat models of neuropathic pain, as well as its side effects on motor, cardiac (heart rate and blood pressure), and biochemical parameters. Methods: Male Wistar rats and male Balb-C mice were used in this study. Giotto Biotech® synthesized the recombinant version of Phα1β using Escherichia coli expression. In rats, neuropathic pain was induced by chronic constriction of the sciatic nerve and paclitaxel-induced acute and chronic pain. Mechanical sensitivity was evaluated using von Frey filaments. A radiotelemeter transmitter (TA11PA-C10; Data Sciences, St. Paul, MN, USA) was placed on the left carotid of mice for investigation of cardiovascular side effects. Locomotor activity data were evaluated using the open-field paradigm, and serum CKMB, TGO, TGP, LDH, lactate, creatinine, and urea levels were examined. Results: Intravenous administration of recombinant Phα1β toxin induced analgesia for up to 4 h, with ED50 of 0.02 (0.01-0.03) mg/kg, and reached the maximal effect (Emax = 100% antinociception) at a dose of 0.2 mg/kg. No significant changes were observed in any of the evaluated motor, cardiac or biochemical parameters. Conclusion: Our data suggest that intravenous administration of recombinant Phα1β may be feasible for drug-induced analgesia, without causing any severe side effects.(AU)

Asunto(s)

RESUMEN

Intrathecal injection of voltage-sensitive calcium channel blocker peptide toxins exerts analgesic effect in several animal models of pain. Upon intrathecal administration, recombinant Phα1ß exerts the same analgesic effects as the those of the native toxin. However, from a clinical perspective, the intrathecal administration limits the use of anesthetic drugs in patients. Therefore, this study aimed to investigate the possible antinociceptive effect of intravenous recombinant Phα1ß in rat models of neuropathic pain, as well as its side effects on motor, cardiac (heart rate and blood pressure), and biochemical parameters. Methods: Male Wistar rats and male Balb-C mice were used in this study. Giotto Biotech® synthesized the recombinant version of Phα1ß using Escherichia coli expression. In rats, neuropathic pain was induced by chronic constriction of the sciatic nerve and paclitaxel-induced acute and chronic pain. Mechanical sensitivity was evaluated using von Frey filaments. A radiotelemeter transmitter (TA11PA-C10; Data Sciences, St. Paul, MN, USA) was placed on the left carotid of mice for investigation of cardiovascular side effects. Locomotor activity data were evaluated using the open-field paradigm, and serum CKMB, TGO, TGP, LDH, lactate, creatinine, and urea levels were examined. Results: Intravenous administration of recombinant Phα1ß toxin induced analgesia for up to 4 h, with ED50 of 0.02 (0.01-0.03) mg/kg, and reached the maximal effect (Emax = 100% antinociception) at a dose of 0.2 mg/kg. No significant changes were observed in any of the evaluated motor, cardiac or biochemical parameters. Conclusion: Our data suggest that intravenous administration of recombinant Phα1ß may be feasible for drug-induced analgesia, without causing any severe side effects.(AU)

Asunto(s)

RESUMEN

Background: Intrathecal injection of voltage-sensitive calcium channel blocker peptide toxins exerts analgesic effect in several animal models of pain. Upon intrathecal administration, recombinant Phα1β exerts the same analgesic effects as the those of the native toxin. However, from a clinical perspective, the intrathecal administration limits the use of anesthetic drugs in patients. Therefore, this study aimed to investigate the possible antinociceptive effect of intravenous recombinant Phα1β in rat models of neuropathic pain, as well as its side effects on motor, cardiac (heart rate and blood pressure), and biochemical parameters. Methods: Male Wistar rats and male Balb-C mice were used in this study. Giotto Biotech® synthesized the recombinant version of Phα1β using Escherichia coli expression. In rats, neuropathic pain was induced by chronic constriction of the sciatic nerve and paclitaxel-induced acute and chronic pain. Mechanical sensitivity was evaluated using von Frey filaments. A radiotelemeter transmitter (TA11PA-C10; Data Sciences, St. Paul, MN, USA) was placed on the left carotid of mice for investigation of cardiovascular side effects. Locomotor activity data were evaluated using the open-field paradigm, and serum CKMB, TGO, TGP, LDH, lactate, creatinine, and urea levels were examined. Results: Intravenous administration of recombinant Phα1β toxin induced analgesia for up to 4 h, with ED50 of 0.02 (0.01-0.03) mg/kg, and reached the maximal effect (Emax = 100% antinociception) at a dose of 0.2 mg/kg. No significant changes were observed in any of the evaluated motor, cardiac or biochemical parameters. Conclusion: Our data suggest that intravenous administration of recombinant Phα1β may be feasible for drug-induced analgesia, without causing any severe side effects.

Asunto(s)

RESUMEN

The in vivo neuroprotective effect of PhTx3-4, a spider toxin N-P/Q calcium channel blocker, was studied in a rat model of NMDA-induced injury of the retina. NMDA (N-Methyl-D-Aspartate)-induced retinal injury in rats reduced the b-wave amplitude by 62% ± 3.6%, indicating the severity of the insult. PhTx3-4 treatment increased the amplitude of the b-wave, which was almost equivalent to the control retinas that were not submitted to injury. The PhTx3-4 functional protection of the retinas recorded on the ERG also was observed in the neuroprotection of retinal cells. NMDA-induced injury reduced live cells in the retina layers and the highest reduction, 84%, was in the ganglion cell layer. Notably, PhTx3-4 treatment caused a remarkable reduction of dead cells in the retina layers, and the highest neuroprotective effect was in the ganglion cells layer. NMDA-induced cytotoxicity of the retina increased the release of glutamate, reactive oxygen species (ROS) production and oxidative stress. PhTx3-4 treatment reduced glutamate release, ROS production and oxidative stress measured by malondialdehyde. Thus, we presented for the first time evidence of in vivo neuroprotection from NMDA-induced retinal injury by PhTx3-4 (-ctenitoxin-Pn3a), a spider toxin that blocks N-P/Q calcium channels.

Asunto(s)

RESUMEN

Introdução: a fisiopatologia da esquizofrenia é ainda pouco esclarecida. Vários estudos descrevem o importante papel da inflamação e do estresse oxidativo nessa explicação. Esquizofrênicos parecem ter seus mecanismos de defesa alterados e resposta distinta dos controles ao estresse oxidativo, que é lesivo a várias estruturas celulares, entre elas a matriz extracelular (MEC). Uma MEC íntegra e estruturada é essencialpara a boa condução sináptica. Objetivo: avaliar a resposta de genes que codificam proteínas da MEC ao estresse oxidativo em esquizofrênicos crônicos e controles. Metodologia: foi feita cultura de fibroblastos a partir de biópsias de pele de esquizofrênicos e controles. Estas foram tratadas com TBHQ, um pró-oxidante, ou DMSO, o veículo, e então se quantificou a expressão dos genes MMP16, GALNT6, SULF1, ADAMTS1 e ACSL1pelo método de PCR em tempo real e dos seus produtos por western blot. Resultados: existe resposta de ambos os grupos ao estresse oxidativo, no entanto, essa resposta é distinta entre pacientes e controles, com esquizofrênicos expressando menos o gene GALNT6 e sua proteína. Conclusão: o gene GALNT6 codifica uma enzima responsável por glicosilar componentes da MEC. Pode-se hipotetizar que a resposta de esquizofrê-nicos ao estresse oxidativo torna essa MEC mais suscetível aos seus efeitos deletérios, colaborando com a fisiopatologia da doença.

Introduction: The pathophysiology of schizophrenia is still poorly understood. Several studies suggest an important role of inflammation and oxidative stress in this explanation. Schizophrenics seem to have altered defense mechanisms and a distinct response to oxidative stress than that of controls. Oxidative stress is harmful to various cellular structures,among them the extracellular matrix (ECM). A intact and structured ECM is essential for proper synaptic signaling. Objective: To evaluate the response of genes encoding ECM proteins to oxidative stress in chronic schizophrenics and controls. Methodology: Fibroblasts were cultivated from schizophrenic and controls? skin biopsies. They were treatedwith TBHQ, a pro-oxidant, or DMSO (the vehicle), and then had the expression of MMP16, GALNT6, SULF1, ADAMTS1 and ACSL1 genes quantified by the method of real time PCR and their products by the method of Western blot. Results: There was response from both groups to oxidative stress, however, this response was different between patients and controls, with schizophrenics expressing less the GALNT6 gene and its protein. Conclusion: GALNT6 gene encodes an enzyme responsible for glycosylating ECM components. We can hypothesize that the schizophrenic?s response to oxidative stress renders the ECM moresusceptible to its harmful effects, contributing to the pathophysiology of the disease.

Asunto(s)

RESUMEN

Voltage-sensitive calcium channels (VSCCs) underlie cell excitability and are involved in the mechanisms that generate and maintain neuropathic and inflammatory pain. We evaluated in rats the effects of two VSCC blockers, ω-conotoxin MVIIA and Phα1ß, in models of inflammatory and neuropathic pain induced with complete Freund's adjuvant (CFA) and chronic constrictive injury (CCI), respectively. We also evaluated the effects of the toxins on capsaicin-induced Ca(2+) influx in dorsal root ganglion (DRG) neurons obtained from rats exposed to both models of pain. A single intrathecal injection of Phα1ß reversibly inhibits CFA and CCI-induced mechanical hyperalgesia longer than a single injection of ω-conotoxin MVIIA. Phα1ß and MVIIA also inhibited capsaicin-induced Ca(2+) influx in DRG neurons. The inhibitory effect of Phα1ß on capsaicin-induced calcium transients in DRG neurons was greater in the CFA model of pain, while the inhibitory effect of ω-conotoxin MVIIA was greater in the CCI model. The management of chronic inflammatory and neuropathic pain is still a major challenge for clinicians. Phα1ß, a reversible inhibitor of VSCCs with a preference for N-type Ca(2+) channels, has potential as a novel therapeutic agent for inflammatory and neuropathic pain. Clinical studies are necessary to establish the role of Phα1ß in the treatment of chronic pain.

Asunto(s)

RESUMEN

Venoms peptides have produced exceptional sources for drug development to treat pain. In this study we examined the antinociceptive and side effects of Tx3-3, a peptide toxin isolated from Phoneutria nigriventer venom, which inhibits high-voltage-dependent calcium channels (VDCC), preferentially P/Q and R-type VDCC. We tested the effects of Tx3-3 in animal models of nociceptive (tail-flick test), neuropathic (partial sciatic nerve ligation and streptozotocin-induced diabetic neuropathy), and inflammatory (intraplantar complete Freund's adjuvant) pain. In the tail-flick test, both intrathecal (i.t.) and intracerebroventricular (i.c.v.) injection of Tx3-3 in mice caused a short-lasting effect (ED(50) and 95% confidence intervals of 8.8 [4.1-18.8] and 3.7 [1.6-8.4] pmol/site for i.t. and i.c.v. injection, respectively), without impairing motor functions, at least at doses 10-30 times higher than the effective dose. By comparison, ω-conotoxin MVIIC, a P/Q and N-type VDCC blocker derived from Conus magus venom, caused significant motor impairment at doses close to efficacious dose in tail flick test. Tx3-3 showed a long-lasting antinociceptive effect in neuropathic pain models. Intrathecal injection of Tx3-3 (30 pmol/site) decreased both mechanical allodynia produced by sciatic nerve injury in mice and streptozotocin-induced allodynia in mice and rats. On the other hand, i.t. injection of Tx3-3 did not alter inflammatory pain. Taken together, our data show that Tx3-3 shows prevalent antinociceptive effects in the neuropathic pain models and does not cause adverse motor effects at antinociceptive efficacious doses, suggesting that this peptide toxin holds promise as a novel therapeutic agent for the control of neuropathic pain. The Brazilian armed spider Tx3-3, a new P/Q and R-type calcium channel blocker, effectively alleviates allodynia in animal neuropathic pain models.

Asunto(s)

RESUMEN

CONTEXTO: O aumento na expectativa de vida e na proporção de idosos na população tem acarretado elevação nas taxas de prevalência de demências. O diagnóstico correto da demência é muito importante para o tratamento clínico e para um melhor prognóstico. Por isso, é necessário adaptar e desenvolver instrumentos para o diagnóstico diferencial entre os processos de envelhecimento normal e patológico. OBJETIVO: Avaliar as propriedades psicrométricas e a estrutura fatorial de um protocolo neuropsicológico usado para avaliação geriátrica. MÉTODO: Pacientes (n = 69) com queixas cognitivas heterogêneas foram avaliados no Núcleo de Geriatria e Gerontologia do Hospital das Clínicas da Universidade Federal de Minas Gerais, a partir de um protocolo composto pelo Miniexame do Estado Mental, Desenho do Relógio, Cubos de Corsi, Fluência Verbal, Span de Dígitos e Token Test. A análise estatística incluiu análise fatorial dos resultados dos testes, correlação de Pearson entre o fator obtido e a idade, escolaridade, anos de educação formal e a Classificação Clínica das Demências (CDR) e a área sob a curva ROC. RESULTADOS: A análise fatorial dos escores do teste mostrou um fator geral representativo que teve associação moderada e significativa com o CDR (r = -0,672; p < 0,001) e anos de educação formal (r = 0,455; p < 0,001). Esse fator teve fraca, mas significativa, correlação com a idade (r = -0,282; p < 0,05). CONCLUSÃO: Esses resultados apontam para uma boa validade de construto e de critério do protocolo na avaliação do declínio cognitivo de idosos. Estudos futuros sobre aplicabilidade e normas populacionais são necessários para aprimorar o uso clínico desse protocolo de avaliação.

BACKGROUND: The increase in life expectancy and proportion of elderly in the population is causing an increase in dementia prevalence rates. The correct, early dia gnosis of dementia is very important to clinical treatment and to improved prognosis. Therefore, it is necessary to adapt and develop assessment tools for the differential diagnosis between pathological and normal aging processes. OBJECTIVE: Assess the psychometric properties and the factorial structure of a neuropsychological protocol used in geriatric assessment. METHOD: Subjects (n = 69) with heterogeneous cognitive complaints were assessed at the Geriatric and Gerontologic Clinic at the Clinical Hospital of the Federal University of Minas Gerais using a protocol composed of the Mini-Mental State Examination, Clock Drawing, Corsi Blocks, Verbal Fluency, Digit Span and Token Test. Statistical analyses included factorial analyses of test results, Pearson's correlation between obtained factor, age, years of formal education and Clinical Dementia Rating (CDR) and area under the ROC curve. RESULTS: The factorial analyses of test scores showed a general representative factor that had moderate and significant association with CDR (r = -0.672; p < 0.001) and years of formal education (r = 0.455; p < 0.001), respectively. This factor had weaker and less significant correlation with age (r = -0.282; p < 0.05). DISCUSSION: These results point to the protocol's good construct and criteria validity in assessing cognitive decline in the elderly. Future works concerning applicability and populational norms are needed to improve the clinical use of this assessment protocol.

Asunto(s)

RESUMEN

The effect of tityustoxin (TsTX) on the release of [3H] dopamine in rat brain prefrontal cortical slices was investigated. The stimulatory effect of TsTX was dependent on incubation time and TsTX concentration with an EC50 of 0.05 microM. The release of [3H] dopamine stimulated by TsTX is dependent of Na+ channels and thus, was completely, inhibited by tetrodotoxin. Tityustoxin-induced release of [3H] dopamine was not blocked by ethylene glycol-bis(beta-aminoethyl) ether (EGTA) and thus was independent of extracellular calcium. However, [3H] dopamine release induced by TsTX was inhibited by 52% by BAPTA, a calcium chelator. Moreover, dantrolene (100 microM) and tetracaine (500 microM) partially inhibited by 38 and 29%, respectively, the tityustoxin-induced release of [3H] dopamine from prefrontal cortical slices suggesting a role from intracellular calcium increase. In conclusion, part of the TsTX-induced release [3H] dopamine may be due to an effect of the toxin on the reversal of the dopamine transporter (DAT), but the majority of the toxin stimulated release of [3H] dopamine involves the mobilization of intracellular calcium stores.

Asunto(s)